VICENTE VALERO to Neutropenia
This is a "connection" page, showing publications VICENTE VALERO has written about Neutropenia.
Connection Strength
0.209
-
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1716-22.
Score: 0.035
-
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
Score: 0.031
-
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct; 16(10):3362-8.
Score: 0.030
-
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol. 1997 Aug; 24(4 Suppl 13):S13-11-S13-18.
Score: 0.028
-
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park). 1997 Aug; 11(8 Suppl 8):34-6.
Score: 0.028
-
Docetaxel and cyclophosphamide in patients with advanced solid tumors. Oncology (Williston Park). 1997 Jun; 11(6 Suppl 6):21-3.
Score: 0.027
-
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul; 19(7):1255-1260.
Score: 0.014
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
Score: 0.008
-
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan; 16(1):187-96.
Score: 0.007